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ABSTRACT
Motivation: In silico prediction of drug–target interactions from
heterogeneous biological data is critical in the search for drugs for
known diseases. This problem is currently being attacked from many
different points of view, a strong indication of its current importance.
Precisely, being able to predict new drug–target interactions with
both high precision and accuracy is the holy grail, a fundamental
requirement for in silico methods to be useful in a biological setting.
This, however, remains extremely challenging due to, amongst other
things, the rarity of known drug–target interactions.
Results: We propose a novel supervised inference method to predict
unknown drug–target interactions, represented as a bipartite graph.
We use this method, known as bipartite local models to ﬁrst predict
target proteins of a given drug, then to predict drugs targeting
a given protein. This gives two independent predictions for each
putative drug–target interaction, which we show can be combined to
give a deﬁnitive prediction for each interaction. We demonstrate the
excellent performance of the proposed method in the prediction of
four classes of drug–target interaction networks involving enzymes,
ion channels, G protein-coupled receptors (GPCRs) and nuclear
receptors in human. This enables us to suggest a number of new
potential drug–target interactions.
Availability: An implementation of the proposed algorithm is
available upon request from the authors. Datasets and all
prediction results are available at http://cbio.ensmp.fr/˜yyamanishi/
bipartitelocal/.
Contact: kevbleakley@gmail.com
Supplementary information: Supplementary data are available at
Bioinformatics online.
1 INTRODUCTION
Thesearchforinteractionsbetweencompounds(ligands,molecules,
drugs) and proteins (targets) is an important part of genomic drug
discovery. Interactions with compounds can affect the action of
many classes of pharmaceutically useful protein targets including
enzymes, ion channels, G protein-coupled receptors (GPCRs)
and nuclear receptors. High-throughput experiments analyzing the
genome, transcriptome and proteome are beginning to lead to
the understanding of genomic spaces populated by these classes
of protein. Simultaneously, high-throughput screening of large
∗To whom correspondence should be addressed.
chemical compound libraries enables us to explore the chemical
space of possible compounds (Dobson, 2004; Kanehisa et al.,
2006; Stockwell, 2000). Chemical genomics research aims to relate
the chemical space with the genomic space in order to identify
potentially useful compound–protein pairs. This said, our current
knowledge about the relationship between these spaces is relatively
limited. The PubChem database at NCBI (Wheeler et al., 2006), for
example, stores information on millions of chemical compounds,
but the number of compounds linked to target proteins remains very
small.Thereis,therefore,astrongincentivetodevelopnewmethods
that are able to predict new compound–protein interactions.
Experimental determination of compound–protein interactions
remains challenging (Haggarty et al., 2003; Kuruvilla et al., 2002).
It is thus of great practical interest to develop genuinely effective in
silico prediction methods which can both provide new predictions to
experimentalists and provide supporting evidence to experimental
results. A variety of such approaches have been developed to
analyze and predict compound–protein interactions. One of the
most commonly used is docking simulations (Cheng et al., 2007;
Rarey et al., 1996). This is relevant when the 3D structure of a
protein is already known, which is unfortunately not often the case,
limiting large-scale implementation. Keiser et al. (2007) provided
a method to predict target protein families based on the known
structures of a set of ligands. However, their approach does not
take advantage of available sequence information of proteins and
predicted interactions were limited to those between known ligands
and different protein families. Another interesting approach by
Campillos et al. (2008) was the use of similarities in the side-
effectsofknowndrugstopredictnewdrug–targetinteractions,some
of which were veriﬁed by in vitro binding assays. The limitation
of this approach is that it only applies to known side-effects of
known drugs, thus limiting the ability of the method to perform
high-throughput screening of potential interactions between new
molecules and proteins.
The current state-of-the-art involves integrative methods that
simultaneously take into account such things as target protein
sequences, drug chemical structures and the currently known drug–
target network. Indeed, Yamanishi et al. (2008) and Yamanishi
(2009) developed supervised learning algorithms to infer unknown
drug–target interactions by integrating the chemical space (e.g.
drug chemical structures) and genomic space (e.g. target protein
sequences)intoauniﬁedspacewhichtheycallthe‘pharmacological
space’. Another encouraging ‘integrative’ research direction is
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the kernel-based approach (Jacob and Vert, 2008; Nagamine and
Sakakibara, 2007) for predicting compound–protein interaction
pairs using a binary classiﬁcation framework. In this context,
compound–protein pairs are taken as inputs for classiﬁers such as
support vector machines (SVMs) with pairwise kernels (pairwise
SVMs). One serious problem with pairwise SVMs is that the
complexity of the ‘training’ phase scales with the square of the
‘number of training ligands times the number of training proteins’,
leading to prohibitive computational difﬁculties for large-scale
problems.
In this article, we propose a novel supervised method to predict
unknown drug–target interactions from chemical and genomic data
that combines the best features of each of these state-of-the-art
techniques; we implement a kernel-based method [e.g. as for Jacob
and Vert (2008)], but with the computational simplicity of the work
of Yamanishi et al. (2008). Our method involves an extension of
the concept of local models (Bleakley et al., 2007; Mordelet and
Vert, 2008) to the bipartite network problem and we use it to
learn and predict protein–compound interaction networks. Local
models are a way to transform edge-prediction problems into well-
known binary classiﬁcation problems of points with labels.Versions
of local models have previously been very successful in learning
and predicting protein–protein interaction and metabolic networks
(Bleakley et al., 2007) and regulatory networks (Mordelet and Vert,
2008).
We then apply the bipartite local models (BLMs) approach
to make predictions for four classes of important drug–target
interactionsinhuman,involvingenzymes,ionchannels,GPCRsand
nuclear receptors. The proposed method is shown to give superior
performance to precursor algorithms of those proposed recently
for drug–target interactions in Yamanishi et al. (2008). Indeed, we
obtained AUC (area under ROC) scores of >97% in some cases
and, more importantly from a biological point of view, AUPR
(area under precision–recall) scores of up to 84%. For example, for
the ion channel benchmark dataset with 1476 known drug–target
interactions (out of a possible 42840), this meant that we achieved
nearly 90% precision at 60% recall. Using an idea that came out
of the BLM approach, we then slightly modiﬁed the comparison
method (Yamanishi et al., 2008) and were able to improve their
own AUC and AUPR scores in certain situations. Simple schemes
for combining BLM predictions and those of the other method
usually further improvedAUC andAUPR results.Acomprehensive
prediction of the four drug–target interaction networks then enabled
us to suggest several new potential drug–target interactions.
2 MATERIALS
2.1 Drug–target interaction data
We obtained information about the interactions between drugs and
target proteins from the KEGG BRITE (Kanehisa et al., 2006),
BRENDA (Schomburg et al., 2004), SuperTarget (Gunther et al.,
2008) and DrugBank (Wishart et al., 2008) databases. At the time
of writing of Yamanishi et al. (2008), the number of known drugs
targeting enzymes, ion channels, GPCRs and nuclear receptors was
found to be 445, 210, 223 and 54, respectively.The number of target
proteins in these classes was found to be 664, 204, 95 and 26 and
the number of known interactions was 2926, 1476, 635 and 90,
respectively. We worked with this exact same dataset as Yamanishi
et al. (2008) in order to facilitate benchmark comparisons between
the two methods. Further details on the curation of these data along
with various statistics on the properties of the four drug–target
interaction networks are given in Yamanishi et al. (2008).
2.2 Chemical data
Chemical structures of the compounds came from the DRUG and
COMPOUND sections in the KEGG LIGAND database (Kanehisa
etal.,2006).Wecomputedthechemicalstructuresimilaritybetween
compounds using SIMCOMP (Hattori et al., 2003), which provides
a global similarity score based on the size of common substructures
between compounds using a graph alignment algorithm. In this
algorithm, the similarity between compounds c and c  is given by
sc(c,c )=|c∩c |/|c∪c |. Applying this operation to all compound
pairs, we constructed a similarity matrix denoted by Sc, which is
considered to represent the chemical space.
2.3 Genomic data
Amino acid sequences of the target proteins were obtained from
the KEGG GENES database (Kanehisa et al., 2006). In this
study, we focused on human proteins. We computed sequence
similarities between proteins using a normalized version of Smith–
Waterman scores (Smith and Waterman, 1981). The normalized
Smith–Waterman score between two proteins g and g  is given by
sg(g,g )=SW(g,g )/

SW(g,g)

SW(g ,g ), where SW(·,·) means
the original Smith–Waterman score. Applying this operation to all
protein pairs, we constructed a similarity matrix denoted Sg, which
is considered to represent the genomic space.
3 METHODS
3.1 The problem of supervised bipartite graph
prediction
We consider the problem of predicting new edges in a partially known drug–
target bipartite network using side information about the vertices. More
precisely, we consider the following framework. Suppose that we have a set
Vd ={d1,d2,...,dm} of drugs (or potential drugs) and a set Vt ={t1,t2,...,tn}
of target (or potential target) proteins. Suppose further that each drug di and
target tj is characterized by a set of pertinent biological data. We make no
restriction requiring that drugs be characterized by the same or similar types
of data as targets. Putting an edge eij between drug di and target tj signiﬁes
that the drug interacts with that target protein, and seen over the whole set
of possible drug–target interactions, this produces a bipartite graph, i.e. a
graph where edges are only allowed to pass between one class of nodes
(drugs) and the other (targets). Therefore, unlike the local model approach
ofBleakleyetal.(2007),thereispotentiallyheterogeneityinthetypesofdata
representing nodes of the same graph, reﬂecting the fact that they are either
drugs or targets, meaning that the previous approach does not immediately
follow over.
3.2 Bipartite graph inference with local models
We propose to solve the bipartite graph inference problem by training several
local models to predict new edges linking drug nodes in Vd with target nodes
in Vt. More precisely, we predict presence or absence of edge eij between
drug di and target tj in the following way.
(1) Excluding target tj, we make a list of all other known targets of di
in the bipartite network, as well as a separate list of the targets not
known to be targeted by di. The known targets are given a label +1
and the others a label −1.
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(2) We look for a classiﬁcation rule that tries to discriminate the
+1-labeleddatafromthe−1-labeleddatausingtheavailablegenomic
sequence data for the targets.
(3) We take this rule and use it to predict the label of tj and hence an edge
or non-edge between di and tj.
(4) We ﬁx the same target tj, then, excluding drug di, we make a list of
all other known drugs targeting tj in the bipartite network, as well as
a list of drugs not known to target tj. Similar to before, drugs known
to target tj are given the label +1 and the others the label −1.
(5) We look for a classiﬁcation rule that tries to discriminate the
+1-labeled data from the −1-labeled data, using the available
chemical structure data for the drugs.
(6) We take this rule and use it to predict the label of di and hence an
edge or non-edge between di and tj.
Part of the originality of the present approach is the steps 4–6, where the
goal is to make a second independent prediction of the same edge, whenever
possible. Even though we are attempting to predict exactly the same edge in
bothcases,wearedoingitwithadifferentdatasetineachcaseandpotentially
adifferentclassiﬁcationrule(orclassofrules).Thisgivesustwoindependent
predictions for the same edge, though with one caveat. In practice, either the
drug may have no known targets or the target may have no known targeting
drug. Results in this article are therefore presented to give a clear idea of
prediction accuracy in each of the following three cases, where for a given
putative drug–target interaction:
• The drug has no known target and the target has at least one known
targeting drug.
• The target has no known targeting drug and the drug has at least one
known target.
• The drug has at least one known target and the target has at least one
known targeting drug.
The ﬁrst two cases reﬂect the situation where we want to predict unknown
interactions involving newly arriving drug–candidate compounds or target–
candidate proteins outside of the training dataset. The third case represents
a kind of ‘double application’ of the algorithm, treating each edge of the
bipartite network as two directed edges pointing in opposite directions. In
this case, we end up with two independent predictions for the same edge.
Essentially, we then deﬁne a function m(·,·) that aggregates the two (or even
more) prediction scores for the same edge into a global score. A simple
heuristic used in this article was the choice m(x,y)=max{x,y}, explored
further in Section 5.
3.3 SVM and kernels
Inthisarticle,followingBleakleyetal.(2007)andMordeletandVert(2008),
we further investigate the use of SVMs as local classiﬁers. These are known
to provide state-of-the-art performance in many applications (Schölkopf
and Smola, 2002; Vapnik, 1998), in particular in computational biology
(Schölkopf et al., 2004). Given biological data about the vertices (either
the drugs or the targets), each local SVM learns from the labels of these
vertices a real-valued function that can then assign a continuous score to the
left-out drug or target. Under the local model framework, this is equivalent
to assigning a score to the left-out edge. Although the {−1,+1} prediction
is usually obtained by simply taking the sign of this score, the value of the
score itself contains some form of conﬁdence in the prediction. We propose
to rank all candidate edges by the value of their SVM prediction. In cases
where we have two scores for candidate edges, we can if we desire ﬁrst
choose a rule to convert these two scores into one score, then rank these
aggregated scores.
A further advantage of SVMs is that they can handle vectorial as well
as non-vectorial data to represent biological data by the use of the so-
called kernel trick (Vapnik, 1998). This means that instead of encoding the
biological information about a drug or target v as a vector Xv, an SVM only
needs the deﬁnition of a positive semi-deﬁnite kernel K(u,v) between any
two vertices derived from biological information. Many particular kernels
for biological data have been developed for various applications in recent
years (Schölkopf et al., 2004), and our approach can therefore fully take
advantage of these results to learn the structure of local networks around
vertices from varied biological data.
3.4 Comparison methods
In order to focus on the differences between the method proposed in this
article and the best results we know of by other methods on the given
benchmark datasets, we provide a detailed comparison with the kernel
regression-based method (KRM) (Yamanishi et al., 2008). We note that this
methodgaveslightlybetterresultsthanthetwomethodsinYamanishi(2009)
(unpublished data). We also provide a comparison with the baseline method
of a nearest neighbor (NN) algorithm. We now brieﬂy recall these methods.
• KRM: ﬁrst, drugs and target proteins on the partially known
interaction network are embedded into a uniﬁed Euclidean space called
the ‘pharmacological space’. Second, a regression model is learned
between the chemical structure (respectively, genomic sequence)
similarity space and the pharmacological space with respect to drugs
(respectively, target proteins). Third, new potential drugs (respectively,
target proteins) are mapped into the pharmacological space. Finally,
predicted interacting drug and target protein pairs are those which are
closertoeachotherthanagiventhresholdinthepharmacologicalspace.
• NN: given a test drug candidate compound, we ﬁnd a known drug
(in the training set) sharing the highest structure similarity with the
new compound, and predict the new compound to interact with target
proteins known to interact with the nearest drug. Likewise, given a
new target candidate protein, we ﬁnd a known target protein (in the
training set) sharing the highest sequence similarity with the new
protein, and predict the new protein to interact with drugs known to
interact with the nearest target protein. Newly predicted compound–
protein interaction pairs are assigned prediction scores with the highest
structure or sequence similarity values involving new compounds or
new proteins in order to draw receiver operating characteristic (ROC)
and PR curves. For more details, see Section 3.1 of Yamanishi et al.
(2008).
3.5 Experimental protocol
In order to compare performance of the methods, we performed systematic
experiments simulating the process of bipartite network inference from
biological data on four drug–target interaction networks. Each experiment
represented a full leave-one-out cross-validation experiment, where one
known edge (or non-edge) is left out and we try to recover its true label
using only the knowledge of the data we have on the drugs and on
the targets, including all other known edges between drugs and targets.
In order to test the robustness of the new method and further quantify
experimental improvements found, we also performed 10 trials of 10-
fold cross-validation of all experiments. The 10-fold results can be found
in Tables 1–4 in the Supplementary Material and also on the web site
(http://cbio.ensmp.fr/˜yyamanishi/bipartitelocal/).
In order to apply SVM-based methods using kernels, we normally require
positive semi-deﬁnite kernel functions Kd and Kt that calculate pairwise
similarities between any pair of drugs and between any pair of targets.
However, for practical applications, in reality all that we need are positive
semi-deﬁnite matrices of pairwise similarities Kd and Kt for sets of given
drugs and targets. The chemical and genomic similarity matrices Sc and Sg
were not all positive semi-deﬁnite, so those that were not were made so by
symmetrizing (adding the transpose and dividing by 2), then adding a small
multiple of the identity matrix to their diagonal until all eigenvalues became
non-negative.These turned out to be very minor modiﬁcations to the original
Sc and Sg. We used the LIBSVM (v.2.88) SVM implementation (Chang and
Lin, 2001) freely available for the MATLAB environment and the R package
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(RDevelopmentCoreTeam,2008)forotherdataanalysisnotrequiringSVM
software.InapplyingtheSVMalgorithmtoourdata,wedidnotusebalanced
penalization in the case of positive and negative training sets of different
sizes. In all experiments, we ﬁxed the C regularization parameter at 1.
The quality of the ranking was assessed using two criteria. First, as in
previous studies, we computed the ROC curve of true positives as a function
of false positives when the threshold to predict interactions from the ranking
varies. The AUC is used to summarize the ROC curve. Although widely
used in classiﬁcation, the AUC criterion is not always relevant for practical
biological applications because there are often magnitudes of order more
negative than positive examples. What matters in practice is that, among
the best ranked predictions that could potentially be experimentally tested,
a sufﬁcient quantity of true positives is present. One way to quantify this
is to look at the PR curve, that is, the plot of the ratio of true positives
among all positive predictions for each given recall rate. The area under this
curve provides a quantitative assessment of how well, on average, predicted
scores of positive examples are separated from predicted scores of negative
examples. The closer the area under this curve (AUPR for area under PR) is
to 1, the better we consider the method to be. In particular, PR curves have
greater biological signiﬁcance than ROC curves for situations where there
are very few positive examples as they punish much more the existence of
false positive examples found among the best ranked prediction scores.
We refer back to Section 3.2 for a description of BLMs. These, in
conjunction with the SVM algorithm provided two independent real-valued
prediction scores for each putative drug–target interaction which could be
combinedtogiveaglobalscoreinvariousways(seeSections4and5).These
scoreswerethenrankedfromsmallesttolargestandcomparedwiththeirtrue
(more correctly, ‘known’) label, i.e. edge or not-known edge. The method
given in Yamanishi et al. (2008) was tested under the same leave-one-out
scheme in order to give directly comparable results.
4 RESULTS
Tables 1–4 give comprehensive results for each of the four
benchmark datasets; KRM (Yamanishi et al., 2008), BLMs and
NN. m is a given function that accepts several predictions for the
same edge and outputs an aggregated prediction. Here, m outputs
the largest score from the set of input scores, though other choices
are possible. Each table is divided into four parts:
• TheﬁrstgivesAUCandAUPRwhenperformingleave-one-out
on potential drugs (d).
• The second gives results when performing leave-one-out on
potential target proteins (t).
• The third gives results when combining two or four leave-one-
out predictions for the same edge.
• The fourth gives results using the NN algorithm and leave-one-
out on potential drugs (d), potential target proteins (t) and the
result obtained when combining the two.
In each table, (*) indicates the original AUC results for the KRM
method (Yamanishi et al., 2008); (**) the best AUC results for
methods introduced in this article and (***) the best AUPR result
across all methods.
We also performed 10 trials of 10-fold cross-validation of
all experimental conditions. These results (with SDs) giving
some idea of the robustness of the algorithm, are shown in
Tables 1–4 of the Supplementary Material and also on the web site
(http://cbio.ensmp.fr/˜yyamanishi/bipartitelocal/) and are in general
accordance with the results we present here for leave-one-out
experiments. These leave-one-out results are separately evaluated
based on the three experimental conditions described in Section 3.
Table 1. Prediction performance for the enzyme dataset
Method AUC AUPR
KRMd 82.8∗ 38.7
BLMd 83.1 40.6
m(KRMd,BLMd) 86.9 39.4
KRMt 92.9∗ 80.6
BLMt 94.2 82.3
m(KRMt,BLMt) 94.4 80.7
m(KRMd,KRMt) 96.7 83.1
m(BLMd,BLMt) 97.3 84.1∗∗∗
m(KRMd,KRMt,BLMd,BLMt) 97.6∗∗ 83.3
NNd 68.2 33.5
NNt 89.9 76.9
m(NNd,NNt) 93.0 63.8
Table 2. Prediction performance for the ion channel dataset
Method AUC AUPR
KRMd 74.5∗ 33.7
BLMd 74.5 33.0
m(KRMd,BLMd) 73.9 33.9
KRMt 91.7∗ 79.6
BLMt 93.5 80.9
m(KRMt,BLMt) 93.5 81.3∗∗∗
m(KRMd,KRMt) 96.9 77.8
m(BLMd,BLMt) 97.0 77.9
m(KRMd,KRMt,BLMd,BLMt) 97.3∗∗ 78.1
NNd 64.7 22.9
NNt 88.7 72.8
m(NNd,NNt) 91.7 53.8
4.1 The drug has no known target and the target has at
least one known targeting drug
This corresponds to rows 1–3 and 10 in Tables 1–4 and refers
to the case where we have a new molecule to screen against the
known drug–target bipartite graph. We see that in seven of the eight
experimental conditions (dataset ∈{1,2,3,4} × {AUC,AUPR}), the
best result comes from the BLMs method or the aggregation of
the scores of the two methods via the function m(KRMd,BLMd) =
max{KRMd,BLMd}.
4.2 The target has no known targeting drug and the
drug has at least one known target
This corresponds to rows 4–6 and 11 in Tables 1–4 and refers to
the case where we have a potential target protein (with no known
targeting drugs) to screen against the known drug–target bipartite
graph. Here, in six of the eight experimental conditions, the best
result comes from the BLM method or the aggregation of the scores
of the two methods via the function m.
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4.3 The drug has at least one known target and the
target has at least one known targeting drug
This corresponds to rows 7–9 and 12 in Tables 1–4 and simulates
the prediction of missing drug–target interactions in the known
bipartite network. Here, we see the signiﬁcant improvement inAUC
and AUPR scores that can be achieved by aggregating the set of
prediction scores for the same drug–target interaction (edge) into a
Table 3. Prediction performance for the GPCR dataset
Method AUC AUPR
KRMd 87.3∗ 40.5
BLMd 82.3 38.8
m(KRMd,BLMd) 88.2 41.4
KRMt 82.8∗ 57.7
BLMt 87.2 56.9
m(KRMt,BLMt) 86.7 57.4
m(KRMd,KRMt) 94.7 66.4
m(BLMd,BLMt) 95.3 66.7∗∗∗
m(KRMd,KRMt,BLMd,BLMt) 95.5∗∗ 66.7∗∗∗
NNd 69.5 32.5
NNt 81.2 52.1
m(NNd,NNt) 88.5 48.5
global prediction score, also illustrated in the PR curves of Figure 1.
We see that in all cases, aggregating scores across the BLM method
or across the two methods gives the best AUC and AUPR scores.
It is important to note that the idea to aggregate scores via a function
m was not used in Yamanishi et al. (2008), so the aggregated results
shown in Tables 1–4 for their method, seen alone, are actually an
improvement on the results shown in their original article.
Table 4. Prediction performance for the nuclear receptor dataset
Method AUC AUPR
KRMd 83.6∗ 43.6
BLMd 81.2 41.3
m(KRMd,BLMd) 85.4 45.0
KRMt 52.3∗ 36.2
BLMt 53.6 35.8
m(KRMt,BLMt) 53.6 36.0
m(KRMd,KRMt) 86.7 61.0
m(BLMd,BLMt) 85.8 60.0
m(KRMd,KRMt,BLMd,BLMt) 88.1∗∗ 61.2∗∗∗
NNd 73.3 40.5
NNt 68.7 42.3
m(NNd,NNt) 85.1 53.6
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Fig. 1. PR curves for predicted drug–target interactions using BLMs on four benchmark datasets: (a) enzyme, (b) ion channel, (c) GPCR and (d) nuclear
receptor. The solid line is for leave-one-out on potential drugs (row 2 of Tables 1–4), the dashed line for leave-one-out on potential target proteins (row 5 of
Tables 1–4) and the dotted line for aggregating the two scores for each putative drug–target interaction (row 8 of Tables 1–4). In the benchmark experiments
(a), (c) and (d), the aggregated curve mimics or gives a signiﬁcant improvement over the other two curves. For ion channels (b), leave-one-out on potential
target proteins (dashed line) perform slightly better overall than aggregation (dotted line), but both curves represent extremely strong results.
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Fig. 2. Part of the predicted interaction network for the nuclear receptor
data. Circles indicate drugs and squares target proteins. Solid edges represent
known interactions and dashed ones show some of the 20 highest scoring
predicted interactions. Dashed edges with asterisks represent compound–
protein interactions now annotated in the SuperTarget database or conﬁrmed
in the literature.
4.4 Global evaluation
The main result is this: the best AUC score for methods introduced
in this article is signiﬁcantly larger than the best score found directly
using the kernel regression method for the four benchmark data sets,
passingrespectivelyfrom92.9to97.6,91.7to97.3,87.3to95.5and
83.6to88.1fortheenzyme,ionchannel,GPCRandnuclearreceptor
data sets. Additionally, the best AUPR scores, more biologically
relevant, also improve across all 4 benchmark data sets, passing
respectively from 80.6t o8 4 .1, 79.6t o8 1 .3, 57.7t o6 6 .7 and 43.6
to 61.2 for the enzyme, ion channel, GPCR and nuclear receptor
data sets.
4.5 New predictions
We focus here on the third experimental condition: prediction of
missing drug–target interactions in the known bipartite graph, as
these results are those which gave a signiﬁcant improvement with
respect to Yamanishi et al. (2008). Essentially, left-out edges that
obtain a high positive prediction score, but which are not known to
be drug–target interactions, are ideal candidates. We calculated the
20highestscoringdrug–targetpairsthatwerenotknowntobedrug–
targetinteractionsatthetimeofwritingofYamanishietal.(2008)for
each of the four datasets.All predictions along with high-resolution
images of the predicted networks for each of the four datasets can
be found in the Supplementary Material and also on the web site
(http://cbio.ensmp.fr/˜yyamanishi/bipartitelocal/). Because of space
limitations, we focus here on the results for nuclear receptors.
Figure 2 shows part of the predicted network for nuclear receptor
data, where edges from the set of the top 20 scoring predictions
are shown as dashed lines. These predicted edges enabled us to
suggest potentially new drug–target relationships. Table 5 shows
the list of the top 10 (of 20) predicted compound–protein pairs, with
biological annotation as given in the KEGG database (Kanehisa
et al., 2006).
Table 5. Top 10 scoring predicted compound–protein pairs for the nuclear
receptor data
Rank Pair Annotation
1 D00094 Tretinoin (JAN/USP/INN)
6095 RORA; RAR-related orphan receptor A
2 D00182 Norethisterone (JP15/INN)
2099 ESR1; estrogen receptor 1
3 D00348 Isotretinoin (USP)
5915 RARB; retinoic acid receptor, beta
4 D00348 Isotretinoin (USP)
5916 RARG; retinoic acid receptor, gamma
5 D00348 Isotretinoin (USP)
6256 RXRA; retinoid X receptor, alpha
6 D00348 Isotretinoin (USP)
6257 RXRB; retinoid X receptor, beta
7 D00348 Isotretinoin (USP)
6258 RXRG; retinoid X receptor, gamma
8 D00094 Tretinoin (JAN/USP/INN)
3174 HNF4G; hepatocyte nuclear factor 4, gamma
9 D00690 Mometasone furoate (JAN/USP)
2908 NR3C1; nuclear receptor subfamily 3,
group C, member 1
10 D00075 Testosterone (JAN/USP)
5241 PGR; progesterone receptor
Pairs in bold are now annotated in the SuperTarget database or conﬁrmed in the
literature.
We used the latest version of the SuperTarget database (Gunther
et al., 2008) as of January 2009 to look for evidence supporting our
approach. Out of our top 10 predictions, three on the list are now in
fact annotated as interacting drug–target pairs: the drug Isotretinoin
(D00348) is linked to the protein RARG (hsa:5916) and to RXRA
(hsa:6256), and the drug Mometasone furoate (D00690) is linked
to the protein NR3C1 (hsa:2908). We did not ﬁnd the predicted
drug–target interaction between Isotretinoin (D00348) and RARB
(hsa:5915) in SuperTarget. However, Lotan et al. (1995) show that
RARB is selectively lost in premalignant oral lesions and can be
restored by treatment with isotretinoin.
To put this result into perspective, we started with a set of
90 known drug–target interactions and 1314 drug–target pairs not
known to interact. Of these 1314, we selected only 20 as the most
likely to be interacting drug–target pairs, and found that at least
4 of the top 10 of them are experimentally veriﬁed drug–target
interactions.We take this as strong evidence supporting the practical
relevance of our approach.
5 DISCUSSION
In this article, we proposed new statistical methods to predict
unknown drug–target interactions from chemical structure
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information and genomic sequence information simultaneously and
on a large scale. The originality of the proposed method lies in the
formalization of bipartite graph inference as a set of independent
local supervised learning problems, each of which predicts which
new drug candidate compounds (respectively, new target candidate
proteins) are connected to each target protein (respectively, each
compound) in the training set. The results we obtained when
predicting human drug–target interaction networks involving
enzymes, ion channels, GPCRs and nuclear receptors demonstrated
the strength of our proposed method for real drug–target prediction
problems, with AUC scores of >97% in some cases and AUPR
scores of up to 84%. Figure 1 indicates that in general, the
information obtained from the amino acid sequence alignments
is more predictive than that obtained from the chemical structure
information, suggesting that one way to improve results would be
to improve the similarity measure between chemical compounds.
Recently added drug–target interactions to the SuperTarget database
(Gunther et al., 2008) and a literature search immediately allowed
us to conﬁrm at least 4 of the 10 most strongly predicted drug–target
interactions for the nuclear receptor dataset obtained using our
method.
Various other computational methods have been developed to
analyze drug–target or compound–protein interactions. A powerful
method is docking simulation (Cheng et al., 2007; Rarey et al.,
1996), but this requires 3D structure information for target proteins.
Most pharmaceutically useful target proteins are membrane proteins
such as ion channels and GPCRs. Determining the 3D structures of
membrane proteins is still quite difﬁcult, which limits the use of
docking. For example, there are only two GPCRs with 3D structure
information (bovine rhodopsin and human β2-adrenergic receptor)
at the time of writing. In the same vein, Campillos et al. (2008)
require side-effect information of the chemical compounds, which
is only well characterized for known drugs. Our method does not
need 3D structure information or side-effect information, it only
requireschemicalstructureinformationofcompoundsandsequence
data of proteins. Thus, an advantage of the method presented here
is that it is suitable for simultaneously screening huge numbers of
drug–candidate compounds and target candidate proteins.
In the present article, we suggested aggregating scores using the
function m(a,b)=max{a,b}. This is a heuristic that appears to work
well for extremely ‘unbalanced’ learning problems where there are
orders of magnitude more of −1 examples than +1, as is the case
here. The vast number of −1 examples has the effect of pulling
all predicted scores closer to −1. Therefore, by taking m as the
max function, we are saying that we give a potential edge a high
aggregated score even if only one of its initial scores escapes the
pull of −1. It remains an open question as to whether there is
some ‘optimal’ way to select a function m. In particular, Table 2
shows that choosing m(a,b)=max{a,b} is perhaps not always a
good idea, especially if one of the two prediction scores for each
edge is systematically of low quality.
Lastly, the method we have proposed belongs to a large general
class of kernel methods (Schölkopf et al., 2004), so we know
that its performance can be potentially improved by using more
sophisticated or biologically relevant kernel similarity functions
designed for genomic sequences (Saigo et al., 2004) and chemical
structures (Mahe et al., 2006).
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